Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 13/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 12/20 | 0.61 |
| ▸ | BCR | P11274 | 9/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.61 |
| ▸ | EGFR | P00533 | 2/20 | 0.60 |
| ▸ | PRKCA | P17252 | 2/20 | 0.60 |
| ▸ | KIT | P10721 | 6/20 | 0.57 |
| ▸ | JAK3 | P52333 | 1/20 | 0.55 |
| ▸ | BTK | Q06187 | 1/20 | 0.55 |
| ▸ | ITK | Q08881 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4891578 | 0.92 | ABL1 (0.72) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL4903331 | 0.89 | ABL1 (0.54) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL14088806 | 0.82 | ABL1 (0.67) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL4899602 | 0.82 | PDGFRA (0.82) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL4900883 | 0.81 | PDGFRA (0.81) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL4897274 | 0.80 | PDGFRA (0.80) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL4903229 | 0.79 | ABL1 (0.76) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL13492352 | 0.78 | PDGFRA (0.69) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL4905663 | 0.78 | PDGFRA (0.62) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL4896195 | 0.78 | ABL1 (0.84) | ABL1PDGFRABCRPDGFRBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786781-A2 | PYRIMIDINE DERIVATIVES | GPC Biotech AG (DE) | 2007-05-23 | — | — | EP | claimed |
| WO-2006021458-A2 | PYRIMIDINE DERIVATIVES | GPC BIOTECH AG (DE) | 2006-03-02 | — | — | WO | claimed |
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | disclosed |
| EP-1786781-A2 | PYRIMIDINE DERIVATIVES | GPC Biotech AG (DE) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006021458-A2 | PYRIMIDINE DERIVATIVES | GPC BIOTECH AG (DE) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080187575-A1 | Pyrimidine Derivatives | TYMP, TDP1, PNP | ABL1 2843/4885PDGFRA 373/4885BCR 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.